IRIS
TALAMONTI, MARINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.371
EU - Europa 1.125
AS - Asia 824
SA - Sud America 10
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 4
AF - Africa 1
Totale 15.343
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.358
SG - Singapore 475
IE - Irlanda 303
CN - Cina 228
IT - Italia 184
DE - Germania 144
UA - Ucraina 115
SE - Svezia 89
RU - Federazione Russa 69
GB - Regno Unito 67
FR - Francia 63
KR - Corea 46
FI - Finlandia 29
IN - India 21
PL - Polonia 14
CA - Canada 11
KG - Kirghizistan 11
ES - Italia 8
BE - Belgio 7
HK - Hong Kong 7
NL - Olanda 7
EU - Europa 6
MY - Malesia 6
UZ - Uzbekistan 6
BR - Brasile 5
CL - Cile 5
CZ - Repubblica Ceca 5
JP - Giappone 5
AU - Australia 4
GR - Grecia 4
TR - Turchia 4
BD - Bangladesh 3
CH - Svizzera 3
IL - Israele 3
RO - Romania 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AT - Austria 2
DK - Danimarca 2
MX - Messico 2
RS - Serbia 2
SI - Slovenia 2
VN - Vietnam 2
EG - Egitto 1
HU - Ungheria 1
IR - Iran 1
KZ - Kazakistan 1
MD - Moldavia 1
MN - Mongolia 1
NO - Norvegia 1
TH - Thailandia 1
Totale 15.343
Salva come PNG Salva come JPEG
Città #
Wilmington 3.391
Houston 3.235
Woodbridge 2.210
Fairfield 911
Chandler 538
Ashburn 502
Seattle 401
Singapore 400
Cambridge 318
Ann Arbor 305
Dublin 286
Medford 214
Beijing 119
Santa Clara 108
Lawrence 103
Dearborn 102
Jacksonville 80
San Diego 65
New York 49
Moscow 45
Rome 44
Munich 29
Zhengzhou 29
Redwood City 25
London 22
Seoul 19
Shanghai 19
Menlo Park 18
Boardman 14
Falls Church 14
Kraków 14
Esslingen am Neckar 13
Milan 13
Pune 13
Norwalk 12
Helsinki 10
Mountain View 10
Saint Petersburg 9
Del Norte 8
Hefei 8
Perugia 8
Brussels 7
Hong Kong 7
Los Angeles 7
Mülheim 7
Detroit 6
Guangzhou 6
Nanchang 6
Nanjing 6
Ottawa 6
Palo Alto 6
San Mateo 6
Brno 5
Frosinone 5
Kilburn 5
Putrajaya 5
Engelhard 4
Nuremberg 4
Renton 4
Washington 4
Casarile 3
Chengdu 3
Council Bluffs 3
Coushatta 3
Hebei 3
Hyderabad 3
Islington 3
Jinan 3
Lausanne 3
Madrid 3
Rapallo 3
Salt Lake City 3
San Giorgio di Nogaro 3
São Paulo 3
Toronto 3
Wandsworth 3
Wuhan 3
Augusta 2
Berlin 2
Bologna 2
Chions 2
Chiswick 2
Clearwater 2
Dhaka 2
Dong Ket 2
General Escobedo 2
Giugliano In Campania 2
Jinhua 2
Kunming 2
Melbourne 2
Monte Vista 2
Pescara 2
Phoenix 2
Piombino Dese 2
San Francisco 2
Shenyang 2
Southwark 2
Sundern 2
Taranto 2
Valencia 2
Totale 13.936
Salva come PNG Salva come JPEG
Nome #
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. 442
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. 442
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study 398
Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis 390
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 387
Tildrakizumab for treating psoriasis 387
Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience 384
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 382
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. 382
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections 370
Brodalumab for the treatment of psoriasis 365
Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients 365
Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. 361
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 359
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 359
Tofacitinib for the treatment of psoriasis 347
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature 342
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 332
A safety evaluation of guselkumab for the treatment of psoriasis 309
A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab 300
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. 296
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 278
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature 271
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy 268
Photo-recall cutaneous reaction to gemcitabine 267
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab 267
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab 251
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial 245
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date 241
Pharmacotherapeutic management of psoriasis in adolescents and children 228
Skin immunity and its dysregulation in psoriasis 221
Successful treatment of psoriatic crumbly nails with ustekinumab 211
The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis 206
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 200
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience 188
Prevalence of cutaneous comorbidities in psoriatic patients and their impact on quality of life 185
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo 170
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis 162
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature 159
Erythrodermic psoriasis treated with ustekinumab: An Italian multicenter retrospective analysis 157
Dupilumab therapy of atopic dermatitis of the elderly: a multi-centre, real-life study 140
The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab 137
Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab 137
Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry 133
Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers 132
Long-term treatment of plaque psoriasis with efalizumab: an Italian experience 122
Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations 115
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab 111
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis 104
Patients with moderate to severe plaque psoriasis: One year after the European medicines agency recommendation of efalizumab suspension 104
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 98
Efalizumab 94
Effect of secukinumab on perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study 89
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab 83
Genetic markers predictive of clinical response to biological drugs in psoriasis. 82
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information 75
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 72
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis 71
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 70
Italian guidelines in diagnosis and treatment of alopecia areata 69
Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines 69
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? 68
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 67
Assessment of HLA Cw6 genotype and correlation to ustekinumab response in a large cohort of patients with moderate-to-severe psoriasis 65
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era 64
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study 64
Adalimumab for moderate to severe psoriasis: an open-label, retrospective 3-year study 64
Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study 60
HLA-Cw6 allele confers sensitivity to efalizumab treatment in psoriasis 60
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis 58
Long-term efficacy of adalimumab in generalized pustular psoriasis 55
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up 53
Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis 52
Linear psoriasis following the typical distribution of the sciatic nerve 48
Clinical severity instruments 48
Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis 47
Human leucocyte antigen Cw6 predisposes to clinical response to the inlterleukin-12/23 blocker ustekinumab: results of long-term treatment 46
Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry 45
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study 44
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies 44
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts 43
HLACw6 predisposes to clinical response to IL12/23 blocker ustekinumab: Results of short- and long-term treatment in anti-TNF naïve patients 43
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis 43
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome 42
Italian Guidelines in Pemphigus - adapted from the European Dermatology Forum (EDF) and European Academy of Dermatology and Venerology (EADV) 41
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis 41
Genetic variations in IL6 and IL12B as protective markers for psoriasis 41
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis 40
Next generation sequencing technology to explore anti-inflammatory activity of IKKa in psoriasis 38
A phase II study of ponesimod in chronic plaque psoriasis: improvements in patient-reported outcomes Abstracts of the 4th Congress of the Psoriasis International Network. July 4-6, 2013. Paris, France 37
The value of genotyping patients for the presence of HLA-C in the personalized treatment of psoriasis 36
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study 35
Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics 33
Pruritus characteristics in a large Italian cohort of psoriatic patients 33
Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry 33
Genetic variati ons in IL6 and IL12B as protecti ve markers for psoriasis Abstracts of the 2013 International Investigative Dermatology Meeting. May 8-11, 2013. Edinburgh, Scotland, United Kingdom 32
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 32
Secukinumab improves patient perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study 30
Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt) 30
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis 29
Totale 15.765
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.144
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.144
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.919 0 0 243 376 393 459 380 384 502 546 336 300
2020/20213.639 331 347 325 385 418 551 469 345 120 170 126 52
2021/20221.173 65 108 107 35 29 52 148 44 93 88 85 319
2022/20231.264 147 132 113 122 80 308 93 62 106 21 48 32
2023/2024530 42 14 23 13 67 121 69 65 4 8 27 77
2024/2025831 122 461 248 0 0 0 0 0 0 0 0 0
Totale 15.967